METABOLIC ACTIVITY DETERMINES SURVIVAL DEPENDING ON THE LEVEL OF LYMPH NODE INVOLVEMENT IN CERVICAL CANCER

Alejandra Martinez, Elodie Chantalat, Martina Aida Angeles, Gwénaël Ferron, Anne Ducassou, Manon Daix, Justine Attal, Sarah Bétrian, Amélie Lusque, Erwan Gabiache. 1Department of Surgical Oncology, Institut Universitaire du Cancer de Toulouse – Oncopole, Toulouse, France; 2Department of Radiotherapy, Institut Universitaire du Cancer de Toulouse – Oncopole, Toulouse, France; 3Department of Oncology, Institut Universitaire du Cancer de Toulouse – Oncopole, Toulouse, France; 4Biostatistics Unit, Institut Universitaire du Cancer de Toulouse – Oncopole, Toulouse, France; 5Department of Nuclear Medicine, Institut Universitaire du Cancer de Toulouse – Oncopole, Toulouse, France

10.1136/ijgc-2022-ESGO.32

Introduction/Background To assess the impact of PET/CT functional parameters on survival, locoregional, and distant failure according to the most distant level of lymph node [18F]FDG uptake in patients with locally advanced cervical cancer (LACC).

Methodology Retrospective study including 148 patients with LACC treated with concurrent chemoradiotherapy after PET/CT and para-aortic lymph node (PALN) surgical staging. Two senior nuclear medicine physicians reviewed all PET/CT exams and retrieved tumor and lymph node metabolic parameters: SUVmax, MTV, TLG. Oncological outcomes according to metabolic parameters and level of lymph node spread on PET/CT were assessed.

Results In patients without lymph node uptake on PET/CT, high MTV values of the cervical tumor were associated with DFS (HR=5.14 95%CI=[2.15–12.31]), OS (HR=6.10 95%CI=[1.89–19.70]), and time to distant (HR=4.73 95%CI=[1.55–14.44]) and locoregional recurrence (HR=5.18 95%CI=[1.72–15.60]). In patients with pelvic lymph node (PLN) uptake but without PALN uptake on [18F]FDG-PET/CT, high MTV values of the cervical tumor were associated with DFS (HR=3.17 95%CI=[1.02–9.83]) and OS (HR=3.46 95%CI=[0.96–12.50]), and the number of PLN fixations was associated with DFS (HR=1.30 95%CI=[1.10–1.53]), OS (HR=1.35 95%CI=[1.11–1.64]), and time to distant (HR=1.35 95%CI=[1.08–1.67]) and locoregional recurrence (HR=1.31 95%CI=[1.08–1.59]). There was no significant association between cervical tumor metabolic or lymph node metrics and survival outcome in patients with PALN uptake.

Conclusion Cervical MTV is more accurate than SUVmax to predict survival outcome in patients with locoregional disease confined to the pelvis and should be implemented in routine clinical practice. Prognostic value of metabolic metrics disappears with PALN uptake, which is associated with distant failure in nearly half of patients.